Effect of Chenodeoxycholic Acid + Ursodeoxycholic Acid to treat dyspepsia

Summaries 3 min 329

Font Size

Created On: 30/07/2022

A multicenter, non-randomized, single-sided preliminary clinical trial was carried out to investigate the safety and efficacy of Chenodeoxycholic and Ursodeoxycholic Acids (CNU) in individuals with refractory functional dyspepsia (RFD).

See All

Key take away

In patients diagnosedf with refractory functional dyspepsia who did not respond to conventional drugs, the use of Chenodeoxycholic Acid and Ursodeoxycholic Acid effectively improved symptoms.

Background

Method

RFD participants were admitted prospectively at six tertiary healthcare facilities. For 12 weeks, all individuals were given CNU twice daily. A track of their complications, drug adherence, and test findings was recorded. It was determined whether 7-point global symptoms scale scores had changed before and after therapy.

The final analysis comprised 37 of the 52 individuals that were prospectively screened. The average age was 51.3 years, with 14 men and 23 females. According to the FD-related medicines consumed,

Notably, 2.4 and 48.2 months were the average number and duration of symptoms prior to therapy. A mean of 3.3 FD-associated drugs was consumed.

Result

The average CNU adherence rate was 95.3%. The mean global symptom scale score dropped from 5.6 before treatment to 2.6 after treatment. The percentage of symptom relief was 94.6%. The only adverse event reported was mild diarrhea (10.8%), which cleared with conservative care.

Conclusion

CNU alleviated RFD in patients who did not show adequate response to standard therapies. Litholytic medicines are effective treatments for people with RFD and biliary dyspepsia secondary to biliary microlithiasis.